share_log

CardioComm Solutions Provides Update Including Trading Reinstatement

CardioComm Solutions Provides Update Including Trading Reinstatement

CardioComm 解决方案提供包括恢复交易在内的更新
newsfile ·  2023/10/04 05:33

Toronto, Ontario--(Newsfile Corp. - October 3, 2023) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, is pleased to provide an update respecting the reinstatement to trading of its common shares on the TSX Venture Exchange (the "Exchange") under the trading symbol "EKG". The Exchange has confirmed that trading of the Company's shares will be reinstated on or about Friday, October 6, 2023.

安大略省多伦多--(Newsfile Corp.——2023年10月3日)- CardioComm 解决方案有限公司 (多伦多证券交易所:EKG) (”心脏通信“或者”公司“) 是一家消费者心脏监测和医疗心电图(“ECG”)软件解决方案的全球医疗提供商,很高兴提供有关恢复其在多伦多证券交易所风险投资交易所(“交易所”)普通股交易的最新消息,交易代码为 “EKG”。联交所已确认,公司股票将于2023年10月6日星期五左右恢复交易。

The Company announced on May 1, 2023, the initial cause for the trading suspension, which was due to the Company not filing its annual financial statements for the financial year ended December 31, 2022 and its management's discussion and analysis relating to the Financial Statements ("Financial Documents") by the May 2, 2023 deadline. The delay was due in part to the March 22, 2023, resignation of Josee Bertrand as the Chief Financial Officer ("CFO") during the time the 2022 year-end independent audit was underway and also to the implementation of a new financial accounting software system. On May 5, 2023, the Ontario Securities Commission issued the Company a failure to file cease trade order ("FFCTO"). The Company filed the Financial Documents on August 3, 2023, and the FFCTO was revoked on August 4, 2023.

公司于2023年5月1日宣布了暂停交易的最初原因,原因是公司没有在2023年5月2日截止日期之前提交截至2022年12月31日的财政年度的年度财务报表,以及管理层在2023年5月2日截止日期之前对财务报表(“财务文件”)的讨论和分析。延迟的部分原因是何塞·伯特兰在2022年年终独立审计进行期间于2023年3月22日辞去首席财务官(“CFO”)的职务,以及新的财务会计软件系统的实施。2023年5月5日,安大略省证券委员会向该公司发布了未能提交停止交易令(“FFCTO”)。该公司于2023年8月3日提交了财务文件,FFCTO于2023年8月4日被撤销。

In order to file the Company's 2022 year-end financial statements as well as the first and second quarter 2023 financial statements, CardioComm's Chief Executive Officer ("CEO"), Etienne Grima, assumed the role of the Company's interim Chief Financial Officer effective August 3, 2023, a role he originally held between 2007 and 2010. While permitted for an interim period, holding such a dual role is in breach of Exchange Policy 3.1, Section 5.9. Accordingly, the TSX Venture Exchange has now permitted trading in the shares of CardioComm to resume while Mr. Grima serves as interim CFO. However, the Company will be placed on a 90-day Notice by the Exchange for non-separation of the CEO / CFO positions during which time the Company will be required to replace Mr. Grima as interim CFO with a dedicated CFO or have its listing transferred to the NEX board of the TSX Venture Exchange. The Company confirms it is in the process of identifying and appointing a CFO and anticipates being in compliance with Exchange Policy 3.1, Section 5.9 in advance of the Notice deadline.

为了提交公司2022年年终财务报表以及2023年第一和第二季度的财务报表,CardioComm的首席执行官(“首席执行官”)艾蒂安·格里玛自2023年8月3日起担任公司临时首席财务官一职,他最初在2007年至2010年期间担任该职务。虽然允许在过渡期内担任这种双重职务,但这违反了交易所政策3.1第5.9节。因此,多伦多证券交易所风险投资交易所现已允许在Grima先生担任临时首席财务官期间恢复CardioComm股票的交易。但是,联交所将向公司发出为期90天的通知,要求其首席执行官/首席财务官职位不分离,在此期间,公司将被要求用专门的首席财务官取代格里马先生担任临时首席财务官,或者将其上市移交给多伦多证券交易所风险投资交易所的NEX董事会。公司确认正在物色和任命首席财务官,并预计在通知截止日期之前遵守交易所政策3.1第5.9节。

The Company also advises of the resignation of Dr. John Foote from his position as a Director of the Company on March 31, 2023. The Company thanks Dr. Foote for his contributions to the Company over his four-year tenure. The Company's current directors and officers are Etienne Grima (Chief Executive Officer, interim Chief Financial Officer, Corporate Secretary and Director), Robet Caines (Director and Chair of the Board) and Daniel Grima (Director). The Company is currently reviewing options to increase its Board of Directors membership.

该公司还表示,约翰·富特博士已于2023年3月31日辞去公司董事职务。公司感谢富特博士在四年任期内为公司做出的贡献。公司现任董事和高管是艾蒂安·格里玛(首席执行官、临时首席财务官、公司秘书兼董事)、罗伯特·凯恩斯(董事兼董事会主席)和丹尼尔·格里玛(董事)。该公司目前正在审查增加董事会成员人数的备选方案。

The Company also wishes to provide an update respecting the cyber security incident on the Company's servers, announced on July 25, 2023. Following the incident, the Company immediately launched a comprehensive investigation and corrective actions plan, working closely with KPMG-EGYDE, relevant authorities and third-party cybersecurity experts in accordance with industry best practices. The Company advises that all production and development systems have been restored.

公司还希望提供有关2023年7月25日宣布的公司服务器网络安全事件的最新情况。事件发生后,该公司立即启动了全面的调查和纠正措施,根据行业最佳实践,与毕马威会计师事务所(KPMG-EGYDE)、相关机构和第三方网络安全专家密切合作。该公司表示,所有生产和开发系统均已恢复。

These have been challenging times for CardioComm, and the Company's Board of Directors and staff are thankful for the patience and continued support of its shareholders, clients and suppliers. The Company confirms it has resumed normal operations and plans to provide further updates soon.

对于CardioComm来说,这是一个充满挑战的时期,公司董事会和员工感谢股东、客户和供应商的耐心和持续支持。该公司确认已恢复正常运营,并计划很快提供进一步的最新信息。

To learn more about CardioComm's products and for further updates please visit the Company's websites at and .

要了解有关CardioComm产品的更多信息以及进一步的更新,请访问该公司的网站,网址为和。

About CardioComm Solutions
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485 and ISO 27001 certifications, is HIPAA compliant and holds medical device clearances and sales licenses from the USA (FDA) and Canada (Health Canada).

关于 CardioComm 解决方案
CardioComm Solutions的专利和专有技术用于记录、查看、分析和存储心电图的产品中,用于心脏病患者的诊断和管理。产品通过外部分销网络和北美销售团队的组合在全球范围内销售。CardioComm Solutions已获得ISO 13485和ISO 27001认证,符合HIPAA标准,并持有美国(FDA)和加拿大(加拿大卫生部)的医疗器械许可和销售许可证。

FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425 x227
investor.relations@cardiocommsolutions.com

欲了解更多信息,请联系:
艾蒂安·格里玛,首席执行官
1-877-977-9425 x227
investor.relations@cardiocommsolutions.com

Forward-looking statements
This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.

前瞻性陈述
本新闻稿可能包含某些前瞻性陈述和前瞻性信息,涉及CardioComm Solutions的财务状况、经营业绩和业务以及CardioComm Solutions与这些项目有关的某些计划和目标。此类陈述和信息反映了管理层当前的信念,并以管理层目前可用的信息为基础。就其本质而言,前瞻性陈述和前瞻性信息涉及风险和不确定性,因为它们与事件有关,取决于未来将发生的情况,并且有许多因素可能导致实际结果和发展与这些前瞻性陈述和前瞻性信息所表达或暗示的结果和进展存在重大差异。

In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).

在评估这些陈述时,读者不应过分依赖前瞻性陈述和前瞻性信息。除非适用法律(包括但不限于美国国家仪器 51-102)第 5.8 (2) 条,否则公司不承担任何义务更新本新闻稿中包含的前瞻性陈述和前瞻性信息 (持续披露义务)。

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

多伦多证券交易所风险投资交易所及其监管服务提供商(该术语在多伦多证券交易所风险投资交易所的政策中定义)均不对本新闻稿的充分性或准确性承担责任。

To view the source version of this press release, please visit

要查看本新闻稿的源版本,请访问

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发